Valor202020212022202320242025TTMGastos comerciales, generales y administrativos92.16 M108.42 M131.4 M161.35 M180.18 M197.56 M197.56 MInvestigación y desarrollo———————Beneficio operativo167.04 M198.62 M278.7 M336.82 M446.87 M534.93 M534.93 MTotal de ingresos no operativos1.49 M3.24 M4.16 M-1.14 M29.05 M7.44 M7.44 MGastos por intereses, netos de intereses capitalizados———————Ingresos no operativos, una vez deducidos los gastos por intereses307 K-105 K-2.9 M-488 K25 M12.78 M12.78 MIngresos/gastos extraordinarios1.18 M3.34 M7.07 M-655 K4.06 M-5.34 M-5.34 MBeneficio antes de impuestos168.53 M201.85 M282.86 M335.68 M475.92 M542.38 M542.38 MParticipación en los beneficios———————Impuestos23.15 M20 M37.49 M52.87 M71.54 M91.25 M91.25 MParticipación minoritaria———————Otros ingresos/gastos después de impuestos22 K-676 K1.51 M-2.71 M4.01 M875 K875 KBeneficio neto antes de actividades interrumpidas145.38 M181.85 M245.37 M282.81 M404.39 M451.12 M451.12 MOperaciones suspendidas———————Beneficio neto145.38 M181.85 M245.37 M282.81 M404.39 M451.12 M451.12 MAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas144.93 M181.39 M245.21 M282.62 M404.34 M451.12 M451.12 MBeneficio básico por acción4.075.067.579.213.0615.6415.64Beneficio por acción diluido3.844.817.288.8812.6315.2815.28Número medio de acciones ordinarias35.63 M35.86 M32.39 M30.72 M30.96 M28.85 M115.97 MAcciones diluidas37.71 M37.7 M33.67 M31.84 M32.01 M29.53 M118.68 MEBITDA186.57 M219.73 M301.04 M363.15 M476.12 M563.06 M563.77 MEBIT167.04 M198.62 M278.7 M336.82 M446.87 M534.93 M534.93 MCosto de los ingresos647.2 M814.22 M1.03 B1.36 B1.45 B1.77 B1.77 BOtros costes de producción647.2 M814.22 M1.03 B1.36 B1.45 B1.77 B1.77 BAmortización y depreciación (flujo de caja)19.53 M21.12 M22.34 M26.33 M29.25 M28.12 M28.83 M
Medpace Holdings Inc
Medpace Holdings, Inc. is a global clinical research organization based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
The company started trading stock as a public firm in 2016.